For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Fibrogen, Inc.

USPTO Granted Patents = 89

% Expired Patents = 20.2

CIPO Patents = 6

EPO Patents = 38

Trademarks = 2

Forward Citations = 958

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Michael P Arend (37 out of 37 patents)

Lee Allen Flippin (32 out of 45 patents)

Volkmar Guenzler-Pukall (27 out of 27 patents)

4. Thomas B Neff (27 out of 27 patents)

5. Stephen J Klaus (21 out of 21 patents)

6. Eric Douglas Turtle (21 out of 28 patents)

7. Wen-Bin Ho (19 out of 20 patents)

8. Todd W Seeley (17 out of 20 patents)

9. Ingrid Langsetmo Parobok (13 out of 13 patents)

10. Xiaohui Du (11 out of 49 patents)

11. Christopher J Molineaux (10 out of 10 patents)

12. Robert C Stephenson (10 out of 10 patents)

13. Jung Min Park (10 out of 10 patents)

14. Michael D Thompson (10 out of 11 patents)

15. David A Yeowell (10 out of 16 patents)

Core Competencies:

Erythropoiesis

Iron Metabolism

HIF Inhibitors

Motor Neuron Diseases

Prolyl Hydroxylase

Pulmonary Fibrosis

Cancer Treatments

Isoquinoline Compounds

Nitrogen-Containing Compounds

Pancreatic Cancer

Kidney Function

Diabetes

89 patents: Sort by Forward Citations

1. 11680048 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

2. 11680047 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

3. 11299537 - Methods for treatment of motor neuron diseases (2022-04-12),

4. 11229637 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2022-01-25),

5. 10927081 - Enhanced erythropoiesis and iron metabolism (2021-02-23),

6. 10894774 - Enhanced erythropoiesis and iron metabolism (2021-01-19),

7. 10882827 - Enhanced erythropoiesis and iron metabolism (2021-01-05),

8. 10765672 - Pharmaceutical formulations of a HIF hydroxylase inhibitor (2020-09-08),

9. 10646482 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2020-05-12),

10. 10626090 - Enhanced erythropoiesis and iron metabolism (2020-04-21),

11. 10555713 - Methods for treating idiopathic pulmonary fibrosis (2020-02-11),

12. 10272078 - Crystalline forms of a prolyl hydroxylase inhibitor (2019-04-30),

13. 10118897 - Crystalline forms of a prolyl hydroxylase inhibitor (2018-11-06),

14. 10092558 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2018-10-09),

15. 10039515 - Methods for treating idiopathic pulmonary fibrosis (2018-08-07),

Fibrogen, Inc., based in San Francisco, CA, specializes in the development of innovative therapies aimed at enhancing erythropoiesis and addressing various medical conditions. The company focuses on core technologies related to iron metabolism, HIF inhibitors, and prolyl hydroxylase, with applications in treating motor neuron diseases, pulmonary fibrosis, and certain cancers. By leveraging its expertise in isoquinoline compounds, Fibrogen aims to create impactful solutions that improve patient outcomes across multiple therapeutic areas.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

89 Patents

#68 in San Francisco, CA

#975 in California

#4,190 in US

#8,600 in the World

San Francisco, CA, United States of America

Fibrogen, Inc.

Forward Citations = 958

78 inventors:

Michael P Arend (37 out of 37 patents)

Lee Allen Flippin (32 out of 45 patents)

Volkmar Guenzler-Pukall (27 out of 27 patents)

4. Thomas B Neff (27 out of 27 patents)

5. Stephen J Klaus (21 out of 21 patents)

Please report any incorrect information to [email protected]

Loading…